Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to $1.4 million.

  • Karyopharm Therapeutics' Change in Accured Expenses fell 7767.28% to $1.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $19.1 million, marking a year-over-year increase of 35377.29%. This contributed to the annual value of $19.1 million for FY2025, which is 35377.29% up from last year.
  • Per Karyopharm Therapeutics' latest filing, its Change in Accured Expenses stood at $1.4 million for Q4 2025, which was down 7767.28% from $9.5 million recorded in Q3 2025.
  • In the past 5 years, Karyopharm Therapeutics' Change in Accured Expenses registered a high of $12.1 million during Q3 2021, and its lowest value of -$9.4 million during Q1 2023.
  • Over the past 5 years, Karyopharm Therapeutics' median Change in Accured Expenses value was $2.3 million (recorded in 2022), while the average stood at $1.7 million.
  • In the last 5 years, Karyopharm Therapeutics' Change in Accured Expenses tumbled by 37351.4% in 2022 and then surged by 1495789.47% in 2025.
  • Karyopharm Therapeutics' Change in Accured Expenses (Quarter) stood at $3.7 million in 2021, then tumbled by 43.34% to $2.1 million in 2022, then soared by 129.16% to $4.8 million in 2023, then soared by 35.08% to $6.5 million in 2024, then crashed by 77.67% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q4 2025, $9.5 million for Q3 2025, and $8.6 million during Q2 2025.